Real-time monitoring of distinct binding kinetics of hot-spot mutant p53 protein in human cancer cells using an individual nanorod-based plasmonic biosensor
- Authors
- Song, Sojin; Lee, Jong Uk; Kang, Jinho; Park, Kyong Hwa; Sim, Sang Jun
- Issue Date
- 1-11월-2020
- Publisher
- ELSEVIER SCIENCE SA
- Keywords
- Breast cancer; Gold nanoparticles (AuNPs); p53 protein; Plasmonic biosensors; Rayleigh scattering
- Citation
- SENSORS AND ACTUATORS B-CHEMICAL, v.322
- Indexed
- SCIE
SCOPUS
- Journal Title
- SENSORS AND ACTUATORS B-CHEMICAL
- Volume
- 322
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/51856
- DOI
- 10.1016/j.snb.2020.128584
- ISSN
- 0925-4005
- Abstract
- Hot-spot mutant p53 proteins are highly associated with cancer malignancy and chemotherapy resistance of various cancers. Precise detection of the hot-spot mutant protein is therefore important in predicting therapeutic effects in cancer. However, conventional analytical methods such as liquid chromatography couple with tandem mass spectrometry (LC-MS/MS) and immunohistochemistry (IHC) have limited sensitivity as well as accuracy and require labor-intensive pretreatment steps. Here, an efficient individual nanorod-based plasmonic biosensor has been developed to detect hot-spot mutant p53 protein with the growth arrest and DNA damage 45 (GADD45) promoter. DNA-protein interactions of wild-type/mutant p53 proteins are kinetically analyzed on the biosensor surface through real-time monitoring of the localized surface plasmon resonance shift, and their dissociation constants and relative transcriptional activities are estimated. Hot-spot mutant proteins exhibited 14.29-fold higher in the dissociation constants and 19.91-fold lower in the relative transcriptional activities as compared to the wild-type proteins. These distinct kinetic values of hot-spot mutants allowed precise detection of hot-spot mutant protein and identification of mutated site of the protein using very small volume of clinical samples. We also demonstrated the clinical validation of the sensor by evaluating its performance in human breast tumor surgical specimens. The sensor's ability to identify the mutant protein with high specificity and extremely low detection limit (11.47 fM) in comparison with the LC-MS/MS and IHC. The results confirmed that our sensor could be characterized as an efficient biosensor for application in clinical assays in terms of analytical performance.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
- College of Engineering > Department of Chemical and Biological Engineering > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.